Lemtrada Better At Preventing MS Relapses Than Rebif, But Did Not Reduce Disability
Lemtrada Better At Preventing MS Relapses Than Rebif, But Did Not Reduce Disability
Although Lemtrada (alemtuzumab) was found to be more effective in preventing MS relapses than the older drug – Rebif – it did not reduce disability in a late-stage clinical trial, the study’s second primary endpoint. In previous studies it had, makers Sanofi and [...]